ProSomnus posts record FY2023 revenue of $27.7M (+43% YoY); reviews financing options

ProSomnus, Inc.

Q4 2023 revenue $7.8M, FY2023 $27.7M; eighth consecutive record quarter.
Operating expenses down 8% vs Q2 2023; 19% improvement as % of revenue.
Cash and restricted cash $7.1M at Dec 31, 2023, down from $12.0M at Sep 30.
Submitted 510(k) for severe OSA label expansion; under substantive FDA review.
Initiated comprehensive review of financing and strategic alternatives.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ProSomnus, Inc. reported financial results for three- and twelve-months ended December 31, 2023.

Period: three- and twelve-months ended December 31, 2023
Result: reported results

Exact text from the filing

On March 26, 2024, ProSomnus, Inc. (“ProSomnus” or the “Company”) issued a press release announcing our financial results for the three- and twelve-months ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-039044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.